|1.||Zarkovic, Neven: 2 articles (11/2005 - 02/2003)|
|2.||Weiss, Thomas: 2 articles (11/2005 - 02/2003)|
|3.||Rusu, Catrinel: 1 article (11/2005)|
|4.||Acalovschi, Iurie: 1 article (11/2005)|
|5.||Sbarcea, Adriana: 1 article (11/2005)|
|6.||Grosu, Vasile: 1 article (11/2005)|
|7.||Dobre, Adrian: 1 article (11/2005)|
|8.||Enesel, Mircea Bogdan: 1 article (11/2005)|
|9.||Klinger, Rainer: 1 article (02/2003)|
|10.||Lungoci, Cornel: 1 article (02/2003)|
11/01/2005 - "The results of this study indicate that perioperative use of the mistletoe drug Isorel can improve immune competence and the overall health status of cancer patients undergoing surgery."
11/01/2005 - "Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients."
02/01/2001 - "Isorel was applied only at the right side (in the limb distal from the tumor) and caused persistent and almost complete inhibition of the tumor growth for 2/7 animals. "
04/01/1997 - "It should be mentioned that the doses of Isorel used in this experiment were much higher than generally used in cancer patients. "
11/01/1993 - "The combined action of Isorel, influencing tumor viability on the one hand and the host's immune reactivity on the other, seems to be favorable for its antitumor action in vivo."
04/01/1997 - "Furthermore, one dose of Isorel (140 mg/kg body weight) restored the suppressed immune response of fibrosarcoma-bearing mice to a significant extent. "
11/01/1993 - "However, a combination of local irradiation and Isorel was very effective: following 43 Gy of local irradiation to a transplanted methylcholanthrene-induced fibrosarcoma (volume about 240 mm3) growing in syngeneic CBA/HZgr mice, the tumor disappeared in about 25% of the animals; the addition of Isorel increased the incidence of cured animals to over 65%. "
|3.||Colorectal Neoplasms (Colorectal Cancer)
02/01/2003 - "The influence of isorel on the advanced colorectal cancer."
02/01/2003 - "Hence, it was further used in a prospective, randomized, and controlled study which compared the postoperative results for patients with colorectal cancer stages Dukes C (40 patients) and D (24 patients) who, beside surgery, received either only chemotherapy (5-FU), 6 cycles (either the Mayo or the De Gramont protocol) or chemotherapy combined with Isorel biotherapy. "
02/01/2003 - "Thus, colorectal cancer patients seem to benefit in terms of survival from combined postoperative chemotherapy and Isorel biotherapy, either adjuvant or palliative."
11/01/2005 - "The study involved 70 cancer patients, divided into two groups: Isorel-treated group of 40 patients who received Isorel for 2 pre- and 2 post-operative weeks (1 esophageal, 16 gastric, 2 pancreatic and 21 colorectal carcinomas) and the age- and sex-matched control group of 30 patients that did not receive Isorel (2 esophageal, 9 gastric, 3 pancreatic, 1 ileac and 15 colorectal carcinomas). "
04/01/1997 - "Injection of Isorel reduced the size of the tumour and caused abundant tumour necrosis with inflammatory response, oedema and destruction of the malignant tissue. "
02/01/2001 - "Histology revealed that Isorel treatment, both at the side of tumor and systemically, increased the incidence of apoptosis and necrosis in the tumors, while reduction of mitosis was noticed only for the tumors in vicinity of the tumor exposed to Isorel. "
|5.||Melanoma (Melanoma, Malignant)
04/01/1997 - "The Viscum album preparation Isorel inhibits the growth of melanoma B16F10 by influencing the tumour-host relationship."
02/01/2003 - "Isorel is aqueous extract well known for its anticancer effects obtained by various in vitro and in vivo experimental models and which was validated by an in vitro bioassay on murine melanoma B16F10 and human cervical carcinoma HeLa cells. "
|3.||Isorel M (Isorel)
|1.||Drug Therapy (Chemotherapy)